MedElevator Войти в исследования
← Поиск публикаций

DOI 10.6004/jnccn.2026.0012

Медицинская библиотека · Journal of the National Comprehensive Cancer Network : JNCCN · 2026

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026.

Wierda William G, Brown Jennifer, Abramson Jeremy S, Awan Farrukh, Bociek Greg, Boyer Daniel, Cortese Matthew, Cripe Larry, D'Angelo Christopher, Darnell Elijah, Davis Randall S, Eradat Herbert, Esteghamat Naseem, Fitzgerald Lindsey, Fletcher Christopher D, Gaballa Sameh, Huntington Scott, Kahl Brad, Kamdar Manali, Kipps Thomas J, Ma Shuo, Mosse Claudio A, Nakhoda Shazia, Parikh Sameer A, Riedell Peter, Schorr Andrew, Schuster Stephen, Seshadri Madhav, Shanafelt Tait, Siddiqi Tanya, Sitlinger Andrea, Thompson Meghan, Ujjani Chaitra, Wagner-Johnston Nina, Woyach Jennifer A, Dwyer Mary, Sundar Hema

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitor (BCL2i)-containing regimens significantly improve survival outcomes in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Results from randomized clinical trials have demonstrated that time-limited treatment with BCL2i-containing regimens resulted in higher rates of undetectable measurable residual disease (uMRD) than BTKi monotherapy or chemoimmunotherapy (CIT). Pirtobrutinib (a noncovalent BTKi) and lisocabtagene maraleucel (CD19-directed CAR T-cell therapy) are newer options for relapsed or refractory disease after prior therapy with BTKi and BCL2i-contining regimens. Histologic transformation of CLL/SLL to diffuse large B-cell lymphoma (Richter transformation) is associated with a poor prognosis. Molecular analysis to determine whether there is clonal relationship between CLL/SLL and transformed diffuse large B-cell lymphoma is useful to select an appropriate treatment option. These NCCN Guideline Insights highlight significant updates to the NCCN Guidelines for the treatment of CLL/SLL and Richter transformation.

Для цитирования: Wierda William G, Brown Jennifer, Abramson Jeremy S, Awan Farrukh, Bociek Greg, Boyer Daniel, Cortese Matthew, Cripe Larry, D'Angelo Christopher, Darnell Elijah, Davis Randall S, Eradat Herbert, Esteghamat Naseem, Fitzgerald Lindsey, Fletcher Christopher D, Gaballa Sameh, Huntington Scott, Kahl Brad, Kamdar Manali, Kipps Thomas J, Ma Shuo, Mosse Claudio A, Nakhoda Shazia, Parikh Sameer A, Riedell Peter, Schorr Andrew, Schuster Stephen, Seshadri Madhav, Shanafelt Tait, Siddiqi Tanya, Sitlinger Andrea, Thompson Meghan, Ujjani Chaitra, Wagner-Johnston Nina, Woyach Jennifer A, Dwyer Mary, Sundar Hema. NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026.. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. DOI: 10.6004/jnccn.2026.0012.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.